Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
CA 2379166 C · Owner: Targeted Genetics Corporation · Inventors: Carter, Barrie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Recombinant viral vectors, especially parvovirus such as adeno-associated virus (AAV) vectors, capable of enhanced expression of heterologous sequences and methods for their construction and use are provided. The vectors have a , structure or are capable of rapidly adopting a structure which involves , intrastrand base pairing of at least one region in a heterologous sequence.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 8, 2000 and granted March 26, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 8, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 8, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.